Marked for destruction

Nature Biotechnology, Published online: 04 June 2026; doi:10.1038/s41587-026-03182-5

The significance of the first FDA-approved PROTAC lies not in proving that targeted protein degradation is superior to conventional therapies, but in proving that degrading proteins is possible as a therapeutic.

A socially assistive robot to support mental wellbeing in LGBTQ+ young people at risk of self-harm: a randomized controlled trial

Nature Medicine, Published online: 04 June 2026; doi:10.1038/s41591-026-04422-6

A randomized controlled trial integrating Purrble, a socially assistive tactile robot, into safety planning found that LGBTQ+ youth at risk of self-harm experienced improvements in Difficulties in Emotion Regulation Scale and fewer depressive symptoms compared to safety planning alone.

How courts are coping with a flood of AI-generated lawsuits

Most days in her chambers, Judge Maritza Braswell, a federal magistrate judge in Colorado, sifts through stacks of documents written by people without a lawyer. Many of them can’t afford to hire a lawyer, and others have cases too weak or too small to interest one. She reads each one carefully, mindful of how daunting it is to walk into the courtroom alone. 

Lately, like many judges across the US, she has seen a noticeable uptick in such filings. According to a new study that examined 4.5 million federal civil cases from 2005 to 2026, the share of lawsuits brought by self-represented people increased from 11% in 2022 to 16.8% in 2025. Within those cases, the number of filings made more than doubled compared to before 2023. 

Judge Braswell puts that jump down to AI. 

“I do correlate that to AI in part because I see AI use,” she says. As a tech-savvy judge who uses AI to vet court documents, she’s learned to recognize how large language models write. She can tell based on the prose and at times, hallucinated cases and fabricated quotes. 

“I’m also actually seeing better-drafted pleadings,” she says. 

But while AI appears to be expanding access to justice, it doesn’t seem to be improving people’s chances of winning. Judges are also starting to question what kinds of rights and responsibilities large language models should bear as they step into lawyers’ shoes, such as whether a chatbot has a duty to provide good advice, as a human lawyer does. And a growing number of lawmakers across the US are starting to grapple with who should pay the price when chatbots dish out bad legal advice. 

AI supercharges lawsuits

To test whether AI was driving the increase in lawsuits filed by people without a lawyer, the authors of the study, Anand Shah at MIT and Joshua Levy at USC, ran 1,600 randomly sampled court documents through Pangram, a commercial AI-text detector. The share flagged as containing AI-generated writing rose from 1% in 2023 to 18% in 2026. 

To Judge Braswell, that’s not necessarily a cause for concern. While the surge of AI-assisted filings might be adding to their workloads, she and many other judges find the cases easier to rule on because AI is helping people without legal training better articulate their arguments. 

Court documents written by people without lawyers are notoriously hard to decipher. Some arrive as handwritten scrawls bordering on gibberish that judges take a while to decode. However cryptic, judges are required to read them charitably.

These days, Judge Braswell has been churning through motions drafted by AI faster than the ones written by the litigants. “I have to be really careful because some of them contain hallucinations and errors, but I can generally understand what they’re arguing better with AI assistance from them than without it,” she says.

The clearer filings let Judge Braswell hear them better. “If I understand an argument a little bit better, I’m probably going to be able to help a little bit more.”

Online communities are springing up to trade self-help guides on using AI to sue. In December 2024, a viral Reddit post walked immigration applicants through suing the United States Citizenship and Immigration Services over delayed review of their applications: draft a writ of mandamus with Microsoft Copilot, pay a lawyer $150 to polish it, and file in the expedient District of Vermont. Cases filed by people without lawyers in Vermont rose from about 45 a year before 2022 to more than 1,100 in 2024. 

Even so, people without lawyers are far more likely to lose their case than people with lawyers, and that’s not changing even with the addition of AI, the study found. 

“It turns out that mounting a lawsuit is a complex, multifaceted task. Not all of it is just drafting text,” says Joshua Levy, a doctoral student at University of Southern California, who co-authored the study. 

Chatbot-client privilege

Judge William Garfinkel, a federal magistrate judge in Connecticut, has served on the bench for three decades, pondering all sorts of questions about lawyers’ relationship with their clients. Lately, he has been wondering whether people’s conversations with chatbots dispensing legal advice should be privileged, the way that their conversations with lawyers are. 

“You can make a good argument that … conversations with large language models like Claude or ChatGPT or Grok should deserve some protection,” he says.

Courts are starting to grapple with this question. In February, a federal court in Michigan ruled that a self-represented person’s conversations with ChatGPT to prepare her case were work product—legal work that is shielded from the opposing side.

The decision came on the same day that a federal court in New York held that documents that a criminal defendant generated using Claude were not privileged attorney-client conversations or work product. The Court argued that Claude is not an attorney and that a user has no “reasonable expectation of confidentiality in his communication” with Claude because AI companies could disclose user data to third parties. 

In March, Judge Braswell also ruled that a self-represented person’s use of a chatbot should stay off limits. “It is true that AI systems like ChatGPT, Claude, Gemini, and others … collect user data for training and other purposes. But … that does not eliminate all expectations of privacy,” she wrote. Courts have since remained split on the issue.

Malpractice without a pulse

Some judges are also wondering whether a chatbot, like a lawyer, has a duty to provide good legal advice. Judge Allison Goddard, a federal magistrate judge in California, has noticed that people without lawyers often get the wrong advice from ChatGPT when trying to assess the value of their case during settlement negotiations. In one case, a plaintiff who slipped and fell in a store asked for $700,000 from the store, which was wildly more than the case was worth.

“Where are you getting the idea that you’re getting $700,000? Did you go to ChatGPT?” Judge Goddard asked. “Well…” the plaintiff mumbled. She then walked them through the law to explain why ChatGPT was wrong and suggested a lower amount. “It’s like Dr. Google went to law school,” she says.

Then there’s the question of who’s liable when a chatbot gives bad legal advice. In March, Nippon Life Insurance Company sued OpenAI alleging that ChatGPT practiced law without a license and helped a woman reopen a lawsuit that was already settled, flooding the court with frivolous filings. “ChatGPT is not an attorney,” the lawsuit said. 

In May, OpenAI asked the court to dismiss the case, arguing that ChatGPT does not practice law. “ChatGPT is not a person and neither has nor uses any degree of legal ​knowledge or skill,” OpenAI said in its filing. The case is still pending before the court.

States have started to weigh legislation that would hold AI companies liable when their chatbots offer bad legal advice. New York introduced a bill in March that would bar chatbots from impersonating lawyers, even if they notify ​users that they are interacting with chatbots. In Congress, a series of bills have been proposed to ban chatbots from posing as lawyers, doctors, and other licensed professionals. The bills have yet to gain traction.

For now, people will continue turning to AI to be their lawyer. For many of them, the rewards outweigh the risks. Not long ago, when Judge Braswell asked a self-represented litigant why they wanted a particular piece of evidence, they mumbled timidly. Now, they answer her questions confidently, having rehearsed with a chatbot. 

“This is a really tough system to navigate. With AI, though, it gets a little less complex,” she says.

STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Revolution Medicines’ daraxonrasib is a certain approval for patients with metastatic pancreatic cancer and tumor progression following chemotherapy. The only gating factor seems to be the speed at which the company can submit the drug to the Food and Drug Administration. Once that happens, daraxonrasib will be cleared quickly and become the new standard of care in the second-line setting.

After the drug’s standing ovation during the ASCO plenary session, the talk shifted to how (and when) the use of daraxonrasib might be expanded to patients with newly diagnosed, metastatic pancreatic cancer.

Continue to STAT+ to read the full story…

What happens at a longevity festival?

The longevity movement is often associated with people that have enough money for a thousand lifetimes — and want to live long enough to spend it all. When my STAT colleague Sarah Todd recently attended the longevity festival known as Vitalist Bay, however, she discovered that the movement isn’t all wealthy Silicon Valley tech bros. 

In this week’s STATus Report, I chat with Sarah about her trip to this California conference, the science of longevity, what the heck a “bodyoid” is, and more. 

Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story

At least 12 of my colleagues boarded planes to the American Society of Clinical Oncology conference in Chicago last week to hear Charles Swanton of the Francis Crick Institute in London share results from the world’s first randomized trial on a multi-cancer early detection test.

The trial — a partnership between the U.K. National Health Service and Grail, which makes the Galleri MCED test — randomized 143,000 average English adults aged 50-77 to receive either usual care or MCED testing. The primary endpoint was reduction of stage 3 and 4 cancers across all cancer types.

Read the rest…